The UNC Breast Cancer SPORE Tissue Procurement &Pathology Core (TPP) Facility is a multifunctional facility, comprised of two parts - Tissue Procurement and Translational Pathology. This Core provides centralized, quality controlled, quality assured procurement, processing, analysis, storage and distribution of normal and malignant breast tissue, blood specimens and other human specimens in support of basic science, translational, genomic, population and clinical trial cancer research. In addition to tissue and blood procurement services, the facility performs extraction of high quality DNA from whole blood, peripheral blood mononuclear cells, buccal smears and mouth rinses and immortalization of breast cancer patient lymphocytes. The Lineberger Data Warehouse (Core B), an Oracle-based, customized user-friendly database, operating on an honest broker model to protect identity and confidentiality, provides the infrastructure to monitor and survey each specimen and associated information. This provides a coordinated system of quality control, sample tracking and distribution of specimens to appropriate investigators. Both the procurement and utilization of breast cancer and control tissues increase substantially in 2010. Breast cancer-specific efforts that have and will support SPORE aims include centralized tissue and specimen banking, receipt and processing of breast-related human specimens including: freshly procured, snap-frozen and formalin fixed paraffin embedded (FFPE) block specimens, preparation of tissue microarrays (TMAs), cell microarrays, morphological evaluation and morphology-based assays (immunohistochemistry, immunofluorescence, in-situ hybridization, and fluorescence in-situ hybridization), assay development &training, and digital imaging and image analysis for spatial quantification of molecular analytes in intact specimens.
The UNC Breast SPORE has heavily integrated tissue and blood-based studies that require a high-performance Biospecimens/Pathology Core. These include high-volume analyses on FFPE tissues for population-based studies (Project 1), high complex analyses on fixed and frozen tissue from clinical trials (Project 3), and frozen tissue procurement and processing for lab-based translational studies (Projects 2, 4, and 5).
|Johnson, Gary L; Stuhlmiller, Timothy J; Angus, Steven P et al. (2014) Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res 20:2516-22|
|Chen, Christina T L; Liu, Ching-Ti; Chen, Gary K et al. (2014) Meta-analysis of loci associated with age at natural menopause in African-American women. Hum Mol Genet 23:3327-42|
|Phillips, Sarah; Prat, Aleix; Sedic, Maja et al. (2014) Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Reports 2:633-47|
|Prat, A; Lluch, A; Albanell, J et al. (2014) Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 111:1532-41|
|Mango, Robert L; Wu, Qing Ping; West, Michelle et al. (2014) C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1. Mol Cancer Res 12:274-82|
|Palmer, Julie R; Viscidi, Emma; Troester, Melissa A et al. (2014) Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst 106:|
|Tao, Jessica J; Castel, Pau; Radosevic-Robin, Nina et al. (2014) Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 7:ra29|
|Mose, Lisle E; Wilkerson, Matthew D; Hayes, D Neil et al. (2014) ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics 30:2813-5|
|Gatza, Michael L; Silva, Grace O; Parker, Joel S et al. (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet 46:1051-9|
|Allott, E H; Tse, C-K; Olshan, A F et al. (2014) Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat 147:415-21|
Showing the most recent 10 out of 276 publications